PROKIDNEY CORP. (PROK)
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
ProKidney Corp.
NASDAQ:PROKHealthcare · Biotechnology
+0.88%$1.15
Prev close$1.140.00%Open$1.14+0.88%Now$1.15
Mkt Cap$347.96M
Float112.16M
O/S209.18M
VOL133K sh
$ Vol$152K
RVOL0.09×
Inst Own24.1%
SI21.9%
EarningsNov 9 · Today
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 1.14 | 1.19 | 1.10 | 1.13 | 133,492 |
| Nov 6, 2026 | 1.05 | 1.16 | 1.04 | 1.14 | 950,922 |
| Nov 5, 2026 | 1.11 | 1.11 | 1.00 | 1.06 | 1,169,584 |
| Nov 4, 2026 | 1.09 | 1.14 | 1.01 | 1.12 | 1,239,812 |
| Nov 3, 2026 | 1.10 | 1.13 | 1.00 | 1.07 | 1,544,110 |
| Nov 2, 2026 | 1.33 | 1.35 | 0.8702 | 1.12 | 7,298,245 |
| Oct 30, 2026 | 1.41 | 1.46 | 1.29 | 1.29 | 1,730,742 |
| Oct 29, 2026 | 1.51 | 1.53 | 1.43 | 1.47 | 821,229 |
| Oct 28, 2026 | 1.47 | 1.59 | 1.46 | 1.52 | 1,497,815 |
| Oct 27, 2026 | 1.39 | 1.55 | 1.35 | 1.51 | 1,367,605 |
| Oct 26, 2026 | 1.41 | 1.44 | 1.35 | 1.36 | 761,676 |
| Oct 23, 2026 | 1.43 | 1.44 | 1.37 | 1.41 | 535,233 |
| Oct 22, 2026 | 1.42 | 1.48 | 1.42 | 1.43 | 584,485 |
| Oct 21, 2026 | 1.44 | 1.49 | 1.44 | 1.44 | 601,290 |
| Oct 20, 2026 | 1.40 | 1.51 | 1.35 | 1.44 | 1,489,346 |
| Oct 19, 2026 | 1.35 | 1.41 | 1.35 | 1.40 | 966,948 |
| Oct 16, 2026 | 1.43 | 1.47 | 1.30 | 1.33 | 1,669,720 |
| Oct 15, 2026 | 1.44 | 1.49 | 1.42 | 1.46 | 1,109,236 |
| Oct 14, 2026 | 1.54 | 1.57 | 1.41 | 1.47 | 2,125,778 |
| Oct 13, 2026 | 1.65 | 1.68 | 1.53 | 1.57 | 1,598,948 |
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not availableRatings Distribution
BUY6
HOLD1
SELL1
TOTAL8
Insider Trades
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Culleton Bruce | Chief Executive Officer | Grant/Award | 500.0K | -- | Nov 2, 2026 |
 Weber Darin J. | Chief Regulatory Officer | Conversion of Derivative | 200.0K | -- | Oct 28, 2026 |
| Weber Darin J. | Chief Regulatory Officer | Conversion of Derivative | 200.0K | -- | Oct 28, 2026 |
| Weber Darin J. | Chief Regulatory Officer | Conversion of Derivative | 200.0K | -- | Oct 28, 2026 |
 Pereira Brian JG | Director | Sale | 27.1K | $38.4K | Aug 20, 2026 |
| Pereira Brian JG | Director | Sale | 222.9K | $316.6K | Aug 20, 2026 |
Shareholders
24.1%
Institutional
(83)
0.6%
Insiderⓘ
(3)
35.3%
5%+ Owners
(1)
40.0%
Unattributed (incl. retail)ⓘ
Institutional24.1%
Insider0.6%
5%+ Beneficial35.3%
Unattributed (incl. retail)40.0%
Top Shareholders
| Name | Shares | % | Source |
|---|---|---|---|
Control Empresarial de Capitales S.A. de C.V. · joint filing· may incl. warrants· filed Apr 2026 | 73.8M | 35.3% | 13D |
MONTANOVA CAPITAL, LLC | 12.3M | 5.9% | 13F |
MORGAN STANLEY | 9.9M | 4.7% | 13F |
Morgan Stanley · also on 13F· joint filing· may incl. warrants· filed Sep 2026 | 9.7M | 4.6% | 13G |
BlackRock, Inc. | 5.2M | 2.5% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 3.6M | 1.7% | 13F |
Bleichroeder LP | 2.0M | 1.0% | 13F |
Artia Global Partners LP | 1.8M | 0.9% | 13F |
Hennion & Walsh Asset Management, Inc. | 1.8M | 0.9% | 13F |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Jul 2025 | 1.8M | 0.8% | 13G |
Sources: 13F, Form 4, 13D/13GO/S: 209.2M · as of 28 Oct 2026 · SEC filings
Insiders & Institutional Holders
Insiders
- Culleton BruceChief Executive Officer
- Weber Darin J.Chief Regulatory Officer
- Pereira Brian JGDirector
- Locke Kenneth ThomasChief Technical Officer
- Girolamo Todd CChief Legal Officer
- Lotvin AlanDirector
- Fox Jennifer A.Director
- DOYLE WILLIAM FDirector
- Legorreta Pablo G.Director
- Sinha UmaDirector
About
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.
It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.
The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Key Metrics
Market Cap$347.96M
Enterprise Value--
P/E Ratio-3.51
Est. Net Cash/Share--
Institutional Ownership24.12%
based on 209.18M shares outstanding
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
Country
US
USIPO DateJun 30, 2021
Shares Outstanding209.18M
Authorized Shares
Float112.16M
52-Week Range
$0.8702$2.95
$1.15(13th percentile)
Volume
Average Daily Volume1.48M
133.49K today vs 1.48M avg(-91%)
30d Avg
1.48M
60d Avg
1.60M
90d Avg
1.48M
Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...